Optimizing Decision-Making in CLL in an Era of Novel Agents

Download All
A comprehensive educational program featuring expert insight commentaries, an Interactive Treatment Decision Support tool, and a series of microeducation modules to fortify your practice in managing patients with CLL.
Jeremy S. Abramson, MD, MMSc
Matthew S. Davids, MD, MMSc
Jeff P. Sharman, MD

Downloadable Slidesets

Download this slideset for expert perspectives on first-line treatment considerations for a patient with CLL with a del(17p) alteration.

Matthew S. Davids, MD, MMSc Released: September 28, 2020

Download this slideset for expert perspectives on first-line treatment considerations for a fit patient with CLL and no high-risk features.

Jeff P. Sharman, MD Released: September 28, 2020

Download this slideset for expert perspectives on first-line treatment considerations for an older patient with CLL.

Jeremy S. Abramson, MD, MMSc Released: October 12, 2020

Download this slideset for expert perspectives on second-line treatment considerations for a patient with CLL who received previous chemoimmunotherapy.

Matthew S. Davids, MD, MMSc Released: September 28, 2020

Download this slideset for expert perspectives on treatment considerations for a patient with CLL who initially progressed on chemoimmunotherapy and was intolerant to subsequent ibrutinib.

Jeff P. Sharman, MD Released: October 1, 2020

Download this slideset for expert perspectives on third-line treatment considerations for patients with CLL requiring new treatment following BTK inhibitor– and venetoclax-based therapy.

Jeremy S. Abramson, MD, MMSc Released: October 14, 2020
Provided by University of South Florida (USF) Health in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
CLL Society Logo
Educational grant provided by:
AbbVie Inc.
AstraZeneca
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings